Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Recent HIV/AIDS News from NIH
October 21, 2013: NIH Officials Map Route Toward an AIDS-Free Generation
“Ending the HIV/AIDS pandemic and achieving an AIDS-free generation will require optimizing the implementation of existing HIV prevention and treatment tools as well as discovering new ones, according to a new commentary from Anthony S. Fauci, M.D., and colleagues at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.”
Read the NIAID press release.
October 17, 2013: NIAID Selects New Director of the Vaccine Research Center
“John R. Mascola, M.D....
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 25, 2013 Category: Infectious Diseases Source Type: news
NIH-funded scientists describe how mosquitoes are attracted to humans
(NIH/National Institute of Allergy and Infectious Diseases) Scientists at the University of California, Riverside have shown that certain mosquito nerve cells, known as cpA neurons, cause mosquitoes to be attracted to humans by detecting exhaled carbon dioxide and odors emitted from human skin. Their findings, published Dec. 5 in the journal Cell, may have implications for the control of mosquitoes and the diseases they transmit. The study was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - December 5, 2013 Category: Infectious Diseases Source Type: news
NIH grantees develop way to make old antibiotic work against TB
(NIH/National Institute of Allergy and Infectious Diseases) Scientists supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have developed a method to synthesize modified forms of an established antibiotic called spectinomycin. The modified forms, unlike the original drug, can act against tuberculosis bacteria. The new compounds overcome a pump mechanism that tuberculosis bacteria ordinarily use to expel standard spectinomycin and were highly effective when tested in mice with either acute or chronic tuberculosis infection.
Source: EurekAlert! - Infectious and Emerging Diseases - January 27, 2014 Category: Infectious Diseases Source Type: news
NIH scientists establish monkey model of hantavirus disease
(NIH/National Institute of Allergy and Infectious Diseases) National Institute of Allergy and Infectious Diseases researchers have developed an animal model of human hantavirus pulmonary syndrome in rhesus macaques, an advance that may lead to treatments, vaccines and improved methods of diagnosing the disease.
Source: EurekAlert! - Infectious and Emerging Diseases - April 28, 2014 Category: Infectious Diseases Source Type: news
Anisakis/Ascaris IgE ratio improves specificity for the diagnosis of Anisakis simplex sensitization in travellers and immigrants.
In conclusion, the ratio of specific IgE to Anisakis and Ascaris improved remarkably the specificity and this parameter easily obtained from the commercially available system could be useful in the diagnosis of hypersensitivity to Anisakis simplex.
PMID: 24911935 [PubMed - as supplied by publisher]
Source: Acta Tropica - June 6, 2014 Category: Infectious Diseases Authors: Carballeda-Sangiao N, Rodríguez-Mahillo AI, Puente S, Gutiérrez MT, Moneo I, González-Muñoz M Tags: Acta Trop Source Type: research
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. CRS3123 (previously known as REP3123) is a narrow-spectrum agent that inhibits C. difficile growth while sparing normal intestinal bacteria.
Source: EurekAlert! - Infectious and Emerging Diseases - July 9, 2014 Category: Infectious Diseases Source Type: news
Experimental chikungunya vaccine induces robust antibody response
(NIH/National Institute of Allergy and Infectious Diseases) An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The results are reported in the current issue of the Lancet.
Source: EurekAlert! - Infectious and Emerging Diseases - August 14, 2014 Category: Infectious Diseases Source Type: news
NIH to Launch human safety study of Ebola vaccine candidate
(NIH/National Institute of Allergy and Infectious Diseases) Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline and will evaluate the experimental vaccine's safety and ability to generate an immune system response in healthy adults. Testing will take place at the NIH Clinical Center in Bethesda, Maryland.
Source: EurekAlert! - Infectious and Emerging Diseases - August 28, 2014 Category: Infectious Diseases Source Type: news
NIAID/GSK experimental Ebola vaccine appears safe, prompts immune response
(NIH/National Institute of Allergy and Infectious Diseases) An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Maryland.
Source: EurekAlert! - Infectious and Emerging Diseases - November 26, 2014 Category: Infectious Diseases Source Type: news
NIH expands early-stage human testing of infectious disease treatment candidates
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.
Source: EurekAlert! - Infectious and Emerging Diseases - January 14, 2015 Category: Infectious Diseases Source Type: news
Ebola vaccine trial opens in Liberia
(NIH/National Institute of Allergy and Infectious Diseases) A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-US clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - February 2, 2015 Category: Infectious Diseases Source Type: news
NIH expands key tuberculosis research program
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is expanding its Tuberculosis Research Units program in an effort to drive innovation in tuberculosis research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.
Source: EurekAlert! - Infectious and Emerging Diseases - February 18, 2015 Category: Infectious Diseases Source Type: news
NIH-funded researchers find off-patent antibiotics effectively combat MRSA skin infections
(NIH/National Institute of Allergy and Infectious Diseases) Researchers funded by the National Institute of Allergy and Infectious Diseases have found that two common antibiotic treatments work equally well against bacterial skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA) acquired outside of hospital settings. Known as community-associated MRSA, or CA-MRSA, these skin infections have been reported in athletes, daycare-age children, students, military personnel and prison inmates, among others, and can lead to hospitalization, surgical procedures, bacteria in the blood, and in severe cases, death.
Source: EurekAlert! - Infectious and Emerging Diseases - March 19, 2015 Category: Infectious Diseases Source Type: news
NIH funds 9 antimicrobial resistance diagnostics projects
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria. The awardee institutions will develop tools to identify certain pathogens that frequently cause infections in health care settings and, specifically, those that are resistant to most antimicrobials.
Source: EurekAlert! - Infectious and Emerging Diseases - April 9, 2015 Category: Infectious Diseases Source Type: news
Mobile phone microscope rapidly detects parasite levels in blood
(NIH/National Institute of Allergy and Infectious Diseases) Scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the University of California, Berkeley, and colleagues have developed a mobile phone microscope to measure blood levels of the parasitic filarial worm Loa loa. The point-of-care device may enable safe resumption of mass drug administration campaigns to eradicate the parasitic diseases onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis).
Source: EurekAlert! - Infectious and Emerging Diseases - May 6, 2015 Category: Infectious Diseases Source Type: news
